PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) Gilberto De Castro,

Slides:

Advertisements

Similar presentations

Volume 389, Issue 10072, Pages (March 2017)

Advertisements

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic.

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao.

Journal of Thoracic Oncology Volume 11, Issue 4, Pages (April 2016)

P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4) Daniel Shao-Weng.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

P Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey Alexis Cortot, Sébastien Couraud,

P Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies Maria Echavarria, Anna.

Journal of Thoracic Oncology Volume 12, Issue 3, Pages (March 2017)

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis Shaohua Lu, Takashi.

MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma Heather Wakelee, Vlada.

Feasibility and Safety of Nonintubated Thoracoscopic Lobectomy for Geriatric Lung Cancer Patients Chun-Yu Wu, MD, Jin-Shing Chen, MD, PhD, Yi-Shiuan.

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris, Meredith.

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC Rafal Dziadziuszko,

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas Hao-Ran Zhai, Jia-Tao Zhang,

MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study Franco.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Journal of Thoracic Oncology Volume 12, Issue 5, Pages (May 2017)

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Journal of Thoracic Oncology Volume 13, Issue 2, Pages (February 2018)

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy You Lu,

Journal of Thoracic Oncology Volume 11, Issue 2, Pages (February 2016)

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

Journal of Thoracic Oncology Volume 12, Issue 7, Pages (July 2017)

Journal of Thoracic Oncology Volume 12, Issue 8, Pages (August 2017)

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study Leena Gandhi, Benjamin Besse, Julien Mazieres,

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

Journal of Thoracic Oncology Volume 11, Issue 10, Pages (October 2016)

Journal of Thoracic Oncology Volume 12, Issue 10, Pages (October 2017)

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis Hossein Borghaei, Julie Brahmer,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Journal of Thoracic Oncology Volume 11, Issue 5, Pages (May 2016)

Journal of Thoracic Oncology Volume 11, Issue 8, Pages (August 2016)

Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non- small Cell Lung Cancer: A Retrospective Multicenter Study Wen-Chien.

Journal of Thoracic Oncology

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC Chanchai Charonpongsuntorn,

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study Edmond Bendaly,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

OA07.06 In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces Takashi Eguchi, Koji.

OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial. J. Mazieres, L. Montané,

Journal of Thoracic Oncology Volume 13, Issue 3, Pages (March 2018)

P Clinical Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Thymic Epithelial Tumor Undergoing Surgery S. Okada, S.

P Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC N. Hardcastle, A. Cole, G. Turgeon, R. Thomas,

European Lung Cancer Conference (ELCC) 2016 Organisation

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

OA Video-Assisted Thoracoscopic Surgery vs

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

MA02.10 The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System H. Hamann, S. Lee, T. Browning, C. Chavez,

PUB001 Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng.

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

Journal of Thoracic Oncology Volume 13, Issue 6, Pages (June 2018)

Journal of Thoracic Oncology

Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar.

Y. Lou, R. Manochakian, J. Cochuyt, D. Hodge, S. Ailawadhi

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) Gilberto De Castro, Daniel Shao-Weng Tan, Lucio Crinò, Yi Long Wu, Luis Paz-Ares, Jürgen Wolf, Sarayut Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu, Maximilian Hochmair, Alexis Cortot, Chun-Ming Tsai, Denis Moro-Sibilot, Rosario García Campelo, Fabrice Branle, Paramita Sen, Tracey Mcculloch, Jean-Charles Soria Journal of Thoracic Oncology Volume 12, Issue 1, (January 2017) DOI: 10.1016/j.jtho.2016.11.008 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, DOI: (10. 1016/j. jtho. 2016. 11 Copyright © 2016 Terms and Conditions